Clinical Trials Logo

Polyomavirus Infections clinical trials

View clinical trials related to Polyomavirus Infections.

Filter by:
  • None
  • Page 1

NCT ID: NCT05325008 Recruiting - Clinical trials for Kidney Transplant Infection

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

BEAT-BK
Start date: August 18, 2023
Phase: Phase 3
Study type: Interventional

BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and simultaneous kidney pancreas transplant recipients with polyomavirus infections (BKPyV).

NCT ID: NCT05224583 Enrolling by invitation - Clinical trials for Kidney Transplant Infection

Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

Start date: November 17, 2021
Phase:
Study type: Observational

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.

NCT ID: NCT03103776 Active, not recruiting - Clinical trials for Thyroiditis, Autoimmune

Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.

IPoTAIG
Start date: March 22, 2016
Phase: N/A
Study type: Interventional

Autoimmune thyroiditis and goitres are frequent pathologies.

NCT ID: NCT02584829 Terminated - Clinical trials for Stage IV Merkel Cell Carcinoma AJCC v7

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Start date: November 6, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and how well localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy works in treating patients with Merkel cell carcinoma that has spread to other parts of the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Interferon beta is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Monoclonal antibodies, such as avelumab, may help T lymphocytes kill tumor cells. For cellular adoptive immunotherapy, specific white blood cells are collected from the patient's blood and treated in the laboratory to recognize Merkel cell carcinoma. Infusing these cells back into the patient may help the body build an effective immune response to kill Merkel cell carcinoma. Giving localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy may be a better treatment for Merkel cell carcinoma.

NCT ID: NCT02479698 Recruiting - Clinical trials for Human Immunodeficiency Virus

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Start date: July 23, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

NCT ID: NCT00160966 Completed - Clinical trials for Polyomavirus Infections

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Start date: September 2004
Phase: Phase 4
Study type: Interventional

The aim of this study is to characterize and evaluate risk factors of polyomavirus nephropathy (PVN) including the impact of three immunosuppressive regimens.